Market Cap (In USD)
794.53 Million
Revenue (In USD)
38.02 Million
Net Income (In USD)
-146.39 Million
Avg. Volume
1.82 Million
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.335-6.055
- PE
- -
- EPS
- -
- Beta Value
- 0.351
- ISIN
- CA00288U1066
- CUSIP
- 00288U106
- CIK
- 1703057
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Carl L.G. Hansen Ph.D.
- Employee Count
- -
- Website
- https://www.abcellera.com
- Ipo Date
- 2020-12-11
- Details
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
More Stocks
-
SBRYJ Sainsbury plc
SBRY
-
8119Sanyei Corporation
8119
-
600592
-
VIVA3
-
3138Auden Techno Corp.
3138
-
088790Jindo.Co., Ltd.
088790
-
MCO
-
2883